Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China

• Published in: Hematology (Luxembourg) 2024-12, Vol.29 (1), p.2310960-2310960
• Main Authors: Ding, Jie, Su, Yang, Ruan, Yinglu, Li, Nan, Meng, Qianchao, Yang, Jiabang, Chen, Li, Liu, Chi
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; allogeneic stem cell transplant; clinical features; MRD; prognosis
• ISSN: 1607-8454; 1607-8454
• DOI: 10.1080/16078454.2024.2310960

To investigate efficacy and prognostic factors in the treatment of adult newly-diagnosed acute myeloid leukemia (AML) with or without allogeneic hematopoietic stem cell transplantation (Allo-HSCT). We retrospectively analyzed 668 patients with newly-diagnosed AML (non-M3 type) in the Department of Hematology at Shanghai Changhai Hospital from January 2012 to December 2021. Based on different induction chemotherapy regimens, patients were categorized into an IA (idarubicin, IDA + cytarabine, Ara-C) (3 + 7, regimen) group (n = 303) and a DA (daunorubicin, DNR + cytarabine, Ara-C) (3 + 7, regimen) group (n = 365) with or without allo-HSCT. Minimal residual disease (MRD), complete response (CR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse effects (AE) were analyzed and compared. Characteristics significantly associated with overall or progression-free survival (OS or PFS) upon univariate analysis were subsequently included in a Cox proportional hazard model. This study used data from 668 AML patients. After induction therapy, the CR rate in the IA group was 70.63% and ORR was 79.87%, which were significantly higher than those in the DA group (with a CR rate of 56.99% and an ORR of 70.14%) (  = 0.0002 and  = 0.0035, respectively). There were no significant differences in drug safety between the two chemotherapy regimens used in IA and DA (  > 0.05). The recurrence rate was lower in patients with an MRD